Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DanCann Pharma AS's annualizedNet Income for the quarter that ended in Sep. 2025 was $-0.98 Mil. DanCann Pharma AS's average total tangible assets for the quarter that ended in Sep. 2025 was $0.82 Mil. Therefore, DanCann Pharma AS's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2025 was -119.85%.
The historical rank and industry rank for DanCann Pharma AS's Return-on-Tangible-Asset or its related term are showing as below:
DCPXF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -373.19 Med: -84.06 Max: -24.74
Current: -151.81
During the past 7 years, DanCann Pharma AS's highest Return-on-Tangible-Asset was -24.74%. The lowest was -373.19%. And the median was -84.06%.
DCPXF's Return-on-Tangible-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.17
vs DCPXF: -151.81
DanCann Pharma AS (GREY:DCPXF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
DanCann Pharma AS Return-on-Tangible-Asset Related Terms
DanCann Pharma AS Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for DanCann Pharma AS's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DCPXF vs ZTS, UTHR, RGC: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DanCann Pharma AS Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where DanCann Pharma AS's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Sep. 2025) net income data.
What does a Return-on-Tangible-Asset of -119.85% mean?
DanCann Pharma AS (DCPXF) has a Return-on-Tangible-Asset of -119.85% as of Sep. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's Return-on-Tangible-Asset too high?
DanCann Pharma AS's current Return-on-Tangible-Asset is -119.85%. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Return-on-Tangible-Asset compare to ZTS and UTHR?
DanCann Pharma AS's Return-on-Tangible-Asset of -119.85% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Asset is 3.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.17, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DanCann Pharma AS and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DanCann Pharma AS's current Return-on-Tangible-Asset is -119.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current Return-on-Tangible-Asset of -119.85%. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current Return-on-Tangible-Asset is -119.85%. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current Return-on-Tangible-Asset is -119.85% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DanCann Pharma AS (DCPXF) Overvalued in 2026?
Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued.
The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.
Key valuation signals for DCPXF:
Return-on-Tangible-Asset: -119.85%
GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score
Get the complete analysis for DCPXF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCPXF has been successfully added to your 
